| Q1 2024 |
39 |
$1.22B |
+$36.9M |
-$48.6M |
-$11.7M |
ACLX, RYTM, SVRA, VRNA, GLUE, NN |
13F-HR |
5/15/2024, 04:44 PM |
| Q4 2023 |
40 |
$1.49B |
+$48.2M |
-$75.3M |
-$27.1M |
COUR, ACLX, RYTM, SVRA, VRNA, CRSP |
13F-HR |
2/14/2024, 05:03 PM |
| Q3 2023 |
42 |
$1.25B |
+$43M |
-$56.5M |
-$13.5M |
COUR, ACLX, SVRA, VRNA, CRSP, MIRM |
13F-HR |
11/14/2023, 01:06 PM |
| Q2 2023 |
43 |
$1.31B |
+$63.8M |
-$329M |
-$266M |
COUR, ACLX, VRNA, CRSP, SVRA, GERN |
13F-HR |
8/11/2023, 04:47 PM |
| Q1 2023 |
53 |
$1.45B |
+$18.8M |
-$117M |
-$98.4M |
COUR, ACLX, VRNA, MIRM, IONQ, NET |
13F-HR |
5/15/2023, 01:36 PM |
| Q4 2022 |
57 |
$1.78B |
+$27.1M |
-$124M |
-$97M |
COUR, ACLX, VRNA, RYTM, BHGXXXX, NET |
13F-HR |
2/10/2023, 01:20 PM |
| Q3 2022 |
57 |
$2B |
+$182M |
-$30.5M |
+$151M |
BHGXXXX, COUR, IONQ, ACLX, RYTM, CRSP |
13F-HR |
11/14/2022, 04:12 PM |
| Q2 2022 |
57 |
$1.95B |
+$98.8M |
-$43.3M |
+$55.4M |
BHGXXXX, COUR, IONQ, ACLX, CRSP, NET |
13F-HR |
8/15/2022, 01:28 PM |
| Q1 2022 |
57 |
$3.46B |
+$104M |
-$36.7B |
-$36.6B |
HOOD, BHGXXXX, IONQ, CRSP, NET, BGRY |
13F-HR |
5/16/2022, 01:36 PM |
| Q4 2021 |
58 |
$4.95B |
+$843M |
-$250M |
+$594M |
HOOD, BHGXXXX, IONQ, COUR, NET, BGRY |
13F-HR |
2/14/2022, 04:03 PM |
| Q3 2021 |
63 |
$8.42B |
+$3.42B |
-$241M |
+$3.18B |
HOOD, BHGXXXX, COUR, CVRX, BGRY, ALLK |
13F-HR |
11/12/2021, 02:50 PM |
| Q2 2021 |
63 |
$7.68B |
+$4.15B |
-$467M |
+$3.69B |
BHGXXXX, COUR, NET, CRSP, DM, ALLK |
13F-HR |
8/2/2021, 11:25 AM |
| Q1 2021 |
58 |
$4.46B |
+$1.14B |
-$109M |
+$1.04B |
COUR, DM, EAR, ALLK, NET, CRSP |
13F-HR |
5/14/2021, 01:47 PM |
| Q4 2020 |
57 |
$3.79B |
+$1.08B |
-$131M |
+$945M |
DM, ALLK, EAR, CRSP, NET, NKTX |
13F-HR |
2/16/2021, 10:15 AM |
| Q3 2020 |
54 |
$2.36B |
+$337M |
-$219M |
+$118M |
SPT, ALLK, ADAP, CRSP, OYST, MRSN |
13F-HR |
11/6/2020, 01:31 PM |
| Q2 2020 |
46 |
$2.49B |
+$114M |
-$116M |
-$2.43M |
SPT, MRSN, OYST, ADAP, ALLK, CRSP |
13F-HR |
8/5/2020, 04:31 PM |
| Q1 2020 |
50 |
$1.91B |
+$226M |
-$710K |
+$226M |
RARX, OYST, SPT, ALLK, NET, ARDX |
13F-HR |
5/6/2020, 04:17 PM |
| Q4 2019 |
47 |
$2.11B |
+$368M |
-$7.3M |
+$361M |
RARX, ALLK, SPT, OYST, CRSP, ARDX |
13F-HR |
1/24/2020, 09:48 AM |
| Q3 2019 |
46 |
$1.21B |
+$121M |
|
+$121M |
ALLK, RARX, RYTM, CRSP, NET, ARDX |
13F-HR |
10/11/2019, 03:19 PM |
| Q2 2019 |
44 |
$1.43B |
+$127M |
-$140M |
-$13.5M |
RARX, GLYC, RYTM, CRSP, ALLK, PHASQ |
13F-HR |
8/7/2019, 11:07 AM |
| Q1 2019 |
45 |
$1.93B |
+$47M |
-$78M |
-$31M |
ESTC, RARX, RYTM, GLYC, ALLK, EPZM |
13F-HR |
5/8/2019, 03:18 PM |
| Q4 2018 |
46 |
$2.52B |
+$521M |
|
+$521M |
TSRO, ESTC, RYTM, ALLK, RARX, ADAP |
13F-HR |
1/18/2019, 11:41 AM |
| Q3 2018 |
44 |
$2.32B |
+$253M |
-$2.13K |
+$253M |
TSRO, ADAP, SENS, RYTM, GLYC, ALLK |
13F-HR |
11/13/2018, 02:31 PM |
| Q2 2018 |
43 |
$2.13B |
+$92.6M |
-$81.9M |
+$10.7M |
TSRO, ADAP, RYTM, GLYC, MRSN, SENS |
13F-HR |
8/9/2018, 03:48 PM |
| Q1 2018 |
43 |
$2.25B |
+$94.3M |
|
+$94.3M |
TSRO, CRSP, ADAP, GLYC, MRSN, EPZM |
13F-HR |
5/10/2018, 01:45 PM |
| Q4 2017 |
43 |
$2.41B |
+$215M |
-$6.75M |
+$208M |
TSRO, GLYC, RYTM, MRSN, DERM, ARDX |
13F-HR |
2/8/2018, 09:12 AM |
| Q3 2017 |
44 |
$2.86B |
+$189M |
|
+$189M |
TSRO, MRSN, EPZM, GLYC, SENS, ADAP |
13F-HR |
11/3/2017, 11:33 AM |
| Q2 2017 |
44 |
$2.75B |
+$205M |
-$35.2M |
+$170M |
TSRO, MRSN, AKAOQ, DERM, GLYC, EPZM |
13F-HR |
7/26/2017, 03:21 PM |
| Q1 2017 |
38 |
$2.88B |
+$101M |
-$21.3M |
+$79.7M |
TSRO, ARDX, AKAOQ, DERM, EPZM, RARX |
13F-HR |
5/10/2017, 04:23 PM |
| Q4 2016 |
39 |
$2.51B |
+$149M |
-$21.9M |
+$127M |
TSRO, ARDX, DERM, EPZM, SENS, AKAOQ |
13F-HR |
2/9/2017, 12:14 PM |
| Q3 2016 |
39 |
$2.23B |
+$51.2M |
-$80.4M |
-$29.2M |
TSRO, ARDX, DERM, GRPNXXXX, SENS, ADAP |
13F-HR |
11/10/2016, 09:53 AM |
| Q2 2016 |
39 |
$1.93B |
+$44M |
-$51.1M |
-$7.1M |
TSRO, GRPNXXXX, SENS, ARDX, DERM, ADAP |
13F-HR |
8/4/2016, 05:40 PM |
| Q1 2016 |
37 |
$1.51B |
+$300M |
-$18.7M |
+$281M |
TSRO, GRPNXXXX, ARDX, ADAP, EPZM, SENS |
13F-HR |
5/11/2016, 05:25 PM |
| Q4 2015 |
34 |
$1.57B |
+$71.1M |
-$10.5M |
+$60.6M |
TSRO, ARDX, GRPNXXXX, DERM, OPWR, EPZM |
13F-HR |
1/22/2016, 01:00 PM |
| Q3 2015 |
35 |
$1.52B |
+$23.9M |
-$929K |
+$23M |
TSRO, ARDX, GRPNXXXX, SUPN, CLVSQ, DERM |
13F-HR |
11/10/2015, 03:42 PM |
| Q2 2015 |
34 |
$1.91B |
+$86.4M |
-$418M |
-$331M |
TSRO, GRPNXXXX, ARDX, SUPN, EPZM, OPWR |
13F-HR |
7/15/2015, 02:40 PM |
| Q1 2015 |
36 |
$2.21B |
+$102M |
-$7.26M |
+$94.9M |
TSRO, GRPNXXXX, CLVSQ, SUPN, HPTX, EPZM |
13F-HR |
5/6/2015, 04:36 PM |
| Q4 2014 |
35 |
$2.06B |
+$91.9M |
-$166M |
-$74.4M |
TSRO, GRPNXXXX, OPWR, CLVSQ, RNA, ARDX |
13F-HR |
1/26/2015, 11:02 AM |
| Q3 2014 |
35 |
$1.97B |
+$228M |
-$67.5M |
+$160M |
GRPNXXXX, TSRO, OPWR, EPZM, CVT, CLVSQ |
13F-HR |
10/24/2014, 03:19 PM |
| Q2 2014 |
31 |
$2.13B |
+$231M |
-$13.1M |
+$218M |
GRPNXXXX, TSRO, EPZM, CVT, OPWR, SUPN |
13F-HR |
7/30/2014, 06:32 PM |
| Q1 2014 |
28 |
$2.04B |
+$206M |
-$92.4M |
+$114M |
GRPNXXXX, TSRO, CVT, CLVSQ, EPZM, GLYC |
13F-HR |
5/1/2014, 01:50 PM |
| Q4 2013 |
29 |
$2.07B |
|
|
|
GRPNXXXX, TSRO, CVT, CLVSQ, EPZM, SUPN |
13F-HR |
1/29/2014, 02:02 PM |